Anterior Skull Base Surgery Center Doctors | NYU Langone Health
Find a doctor at the Anterior Skull Base Surgery Center at NYU Langone.
Anti-Viral Therapy in Alzheimer's Disease
This study is being conducted to evaluate if the generic anti-viral medication,valacyclovir, is helpful in treating Alzheimer’s disease in patients who have tested positive for antibodies to herpes simplex virus-1 or herpes simplex virus-2 in their blood serum. This study will examine the effects of valacyclovir or placebo on everyday cognition (learning, memory, attention, language, and related mental abilities) and function over an 18-month period.
Antibiotic-Resistant Infections | NYU Langone Health
NYU Langone doctors identify and manage antibiotic-resistant infections, such as MRSA and carbapenem-resistant Enterobacteriaceae.
Anticoagulation for Stroke Prevention and Recovery after ICH (ASPIRE)
Survivors of intracerebral hemorrhage (ICH) who have atrial fibrillation/flutter (AF) are at high risk for subsequent ischemic stroke. Although randomized clinical trials have established the of anticoagulant therapy for preventing ischemic stroke in patients with AF,1 these trials did not enroll ICH patients because of concern that a potential increase in risk for recurrent hemorrhagic strokes would offset any benefit. As a result, American Heart Association/American Stroke Association guidelines equivocate on whether to use anticoagulants in patients with AF after ICH2 and only a minority of these patients are currently offered this therapy.3,4 The Anticoagulation for Stroke Prevention and Recovery after ICH (ASPIRE) study is a randomized,double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF (CHA2DS2-VASc score = 2). A total of 700 patients, age 18 years or older, with a first-ever ICH 14-120 days before entry will be randomized in a 1:1 ratio to receive apixaban (5 mg tablets twice daily, or 2.5 mg tablets twice daily for patients meeting standard dose-adjustment requirements) or aspirin (81 mg tablet once daily). Participants will be followed for study outcomes for a median of 24 months (minimum 12 months, maximum 36 months). The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Tertiary efficacy and safety outcomes include change in cognition and quality of life, major hemorrhage, myocardial infarction, and individual components of the primary outcome. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.
Antiphospholipid Syndrome | NYU Langone Health
NYU Langone doctors quickly diagnose and develop a treatment plan to manage the symptoms of antiphospholipid syndrome.
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTIONInternational Clinical Database and Repository
Antiphospholipid syndrome (APS) is a disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss. APS can occur as a primary condition or secondary to an autoimmune disease such as systemic lupus erythematosus (SLE)(1). The aim of this study is to establish a registry or database to assess outcomes, response to treatment, treatment preferences and disease characteristics of patients with Primary Antiphospholipid Syndrome (PAPS) and also of those with APS secondary to SLE. A registry with a collection of clinical data with a large cohort will identify areas to conduct clinical trials. Currently, clinical trials are needed to increase evidence base and optimize the management of APS (4). In addition, any differences of outcomes of those with PAPS compared with APS and SLE will be evaluated. Literature review revealed conflicting reports Vianna, JL, et al, observed similar outcomes in these cohorts (2). In contrast, Danowski, A, et al, suggest those with APS and SLE have an increased incidence of arterial thrombosis, venous thrombosis, and fetal loss than in those with primary APS (3). The outcomes of these types of studies will offer support for rheumatologists monitoring patients with APS. 200 subjects will be enrolled at this site.
Antiretroviral Therapy for Kaposi Sarcoma | NYU Langone Health
NYU Langone doctors prescribe antiretroviral medications for people with HIV and Kaposi sarcoma.
Anxiety Disorders | NYU Langone Health
NYU Langone mental health specialists manage a broad range of anxiety disorders.
Anxiety Disorders in Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat childhood anxiety disorders.
Aortic Aneurysm | NYU Langone Health
NYU Langone vascular and cardiothoracic surgeons are highly trained in diagnosing and managing aortic aneurysms.